A Business Model Concentrating Resources on R&D and Manufacturing through Sales-Partner Outsourcing
First written in FY2025-H1. 2 of 3 entries say "Restated". Latest entry: 2026-08-05.
3 other companies' latest entry also says "Restated".
- 2026-08-05RestatedEarnings
「We do not have a pharmaceutical sales division. Instead, we operate a business model that focuses our management resources on research and development and manufacturing by partnering with companies in Japan and overseas that have strengths in the respective product areas and outsourcing sales to them.」
The company reaffirmed its business model of concentrating management resources on research and development and manufacturing by outsourcing sales to sales partners. - FY2026-H1RestatedAnnual report
「We do not have a pharmaceutical sales division. Instead, we operate a business model that focuses our management resources on research and development and manufacturing by partnering with companies in Japan and overseas that have strengths in the respective product areas and outsourcing sales to them.」
The company continues to outsource pharmaceutical sales to domestic and overseas commercial partners and concentrate its management resources on R&D and manufacturing. - FY2025-H1First statedAnnual report
「We do not have a pharmaceutical sales division. Instead, we operate a business model that focuses our management resources on research and development and manufacturing by partnering with companies in Japan and overseas that have strengths in the respective product areas and outsourcing sales to them.」
The company explicitly described its business model of outsourcing pharmaceutical sales to domestic and overseas commercial partners and concentrating its management resources on R&D and manufacturing.